Does Rallies show 13F holders for TRVI?

Yes. Rallies tracks hedge fund and 13F ownership data for TRVI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TRVI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRVI. It does not provide personalized investment advice.

TRVI (Trevi Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Trevi Therapeutics, Inc. Common Stock (TRVI) is a publicly traded Healthcare sector company. As of May 21, 2026, TRVI trades at $13.88 with a market cap of $1.91B and a P/E ratio of -29.24. TRVI moved +4.83% today. Year to date, TRVI is +22.18%; over the trailing twelve months it is +114.53%. Its 52-week range spans $2.36 to $16.12. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces TRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TRVI stock?

Hedge funds tracked by Rallies that own TRVI include Viking Global, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Trevi Therapeutics, Inc. Common Stock.

TRVI Key Metrics

Key financial metrics for TRVI
Metric	Value
Price	$13.88
Market Cap	$1.91B
P/E Ratio	-29.24
EPS	$-0.47
Dividend Yield	0.00%
52-Week High	$16.12
52-Week Low	$2.36
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-47.91M
Gross Margin	0.00%

Top Hedge Funds Holding TRVI

Viking Global holds 3.20M shares of TRVI, changed +0.00% as of Mar 31, 2026.
Orbimed Advisors holds 2.45M shares of TRVI, changed -23.08% as of Mar 31, 2026.
Panagora Asset holds 625.58K shares of TRVI, changed -9.73% as of Mar 31, 2026.

Latest TRVI News

Trevi Therapeutics Raises $162M, Extends Cash Runway into 2030 and Plans Phase 3 in IPF — May 5, 2026
Trevi to Present CORAL Analyses and Drug–Drug Interaction Data at ATS 2026 Orlando — Apr 30, 2026
Trevi Therapeutics Schedules May 7 NYC Investor Day, May 12 BofA Presentation and May 18 ATS Session — Apr 23, 2026
Trevi Therapeutics Secures $173 Million in Fully Exercised Share Offering — Apr 20, 2026
Trevi Therapeutics Secures $188M Cash Runway into 2028, Plans Two Phase III Trials — Mar 18, 2026

Recent TRVI Insider Trades

SCIASCIA THOMAS sold 2.63K (~$17.36K) on Mar 25, 2025.
GOOD JENNIFER L sold 5.26K (~$34.62K) on Mar 21, 2025.
Simon Farrell sold 76.96K (~$517.78K) on Mar 10, 2025.

TRVI Analyst Consensus

8 analysts cover TRVI: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.50.

Common questions about TRVI

Who owns TRVI stock?: Hedge funds tracked by Rallies that own TRVI include Viking Global, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Trevi Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for TRVI?: Yes. Rallies tracks hedge fund and 13F ownership data for TRVI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TRVI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRVI. It does not provide personalized investment advice.